Selection‐based design of in silico dengue epitope ensemble vaccines,Chemical Biology & Drug Design

当前位置： X-MOL 学术 › Chem. Bio. Drug Des. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Selection‐based design of in silico dengue epitope ensemble vaccines
Chemical Biology & Drug Design ( IF 3.2 ) Pub Date : 2018-11-25 , DOI: 10.1111/cbdd.13357
David Murphy ₁ , Pedro Reche ₂ , Darren R. Flower ₁

Affiliation

Dengue virus affects approximately 130 countries. Twenty‐five percentage of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal dengue haemorrhagic fever or dengue shock syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target dengue, we used an innovative immunoinformatics protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly conserved epitopes with experimentally verified immunogenicity. From 1597 CD4+ and MHC II epitopes, six MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY and WAYHGSYEV) and nine MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ and WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.

中文翻译：

基于登革热的登革热表位整合疫苗设计

登革热病毒影响大约130个国家。25％的感染导致发热，自限性疾病；异型感染会导致潜在的致命登革出血热或登革热休克综合征。当前仅提供一种疫苗。其功效是非常可变的。因此，针对登革热，我们使用了创新的免疫信息学方案，通过选择一组最佳的高度保守的抗原决定簇，并通过实验验证了免疫原性，设计了一种假定的抗原决定簇整合疫苗。从1597 CD4 +和MHC II表位开始，六个MHC I类表位（RAVHADMGYW，GPWHLGKLEM，GLYGNGVVTK，NMIIMDEAHF，KTWAYHGSY和WAYHGSYEV）和九个MHC II类表位（LAKAIFKLTYQNKVV，GKIVGLYGNGVAVTGTA，ATKAVTGVATGVATGTAVTGTSVATGATVATGTA 选择了VGTYGLNTFTNMEVQ和WTLMYFHRRDLRLAA；该候选疫苗的全球人口覆盖率为92.49％。

更新日期：2018-11-25

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11